• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . The importance of fecal nucleic acid detection in patients with coronavirus disease(COVID-19):a systematic review and meta-analysis

tetano

Editor, Senior Moderator
J Med Virol


. 2022 Feb 16.
doi: 10.1002/jmv.27652. Online ahead of print.
The importance of fecal nucleic acid detection in patients with coronavirus disease(COVID-19):a systematic review and meta-analysis


Jin-Qiu Zhou[SUP] 1 2 [/SUP], Gong-Xiang Liu[SUP] 1 2 [/SUP], Xiao-Li Huang[SUP] 1 [/SUP], Hua-Tian Gan[SUP] 1 [/SUP]



Affiliations

Abstract

Results: Pooled data from 2,352hospitalized COVID-19 patients with viral RNA in feces across 46 studies were analyzed, and the pooled prevalence of fecal RNA was 46.8% (95% confidence interval [CI] 0.383-0.554). The pooled analysis showed that the occurrence of total gastrointestinal (GI) symptoms was 28.5% (95% CI 0.125-0.44) in COVID-19 patients with fecal RNA, that of both respiratory and GI symptoms was 21.9% (95% CI 0.09-0.346), that of only GI symptoms was 19.8% (95% CI 0.107-0.288), and that of only respiratory symptoms was 50.5%(95% CI 0.267-0.744). The pooled data showed no significant difference in positive fecal RNA between severe and non-severe cases (OR = 2.009, P = 0.079, 95% CI 0.922-4.378). During hospital admission, after samples from the respiratory system tested negative for viral RNA, 55.4% (95% CI 0.418-0.669) of the patients with positive fecal RNA had persistent shedding of fecal RNA, and pooled results from the other 4 studies including 848 discharged patients with nucleic acid-negative stool samples indicated that the occurrence of re-positive stool swabs was 18.1% (95% CI 0.028-0.335), that of re-positive respiratory swabs was 22.8% (95% CI 0.003-0.452), that of both re-positive stool and respiratory swabs was 19,1% (95% CI 0.019-0.363), and that of only re-positive stool swabs was 9.6% (95% CI 0.010-0.203).
Conclusions: The digestive tract may be an important organ involved in COVID-19 infection and in the excretion of the virus. Because of the potential risk of fecal-oral transmission, giving emphasis on stool swab tests can help increase the detection rate of asymptomatic carriers and reduce missed diagnoses. This article is protected by copyright. All rights reserved.

Keywords: COVID-19; fecal; meta-analysis; systematic review.
 
Back
Top Bottom